Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients (AIR-CF5)

This study is ongoing, but not recruiting participants.
Cystic Fibrosis Foundation Therapeutics
Information provided by (Responsible Party):
Gilead Sciences Identifier:
First received: June 15, 2011
Last updated: September 25, 2015
Last verified: September 2015
This is a prospective, longitudinal, 5-year study that will enroll participants from the existing Cystic Fibrosis Foundation (CFF) patient registry. Each enrolled participant will provide samples for microbiological evaluation, obtained upon enrollment and then once per year thereafter for 5 years.

Cystic Fibrosis

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Prospective, 5-year Registry Study to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa (PA) Isolates From Patients With Cystic Fibrosis in the United States [AIR-CF5]

Resource links provided by NLM:

Further study details as provided by Gilead Sciences:

Primary Outcome Measures:
  • Proportion of participants whose least susceptible Pseudomonas aeruginosa (PA) isolate has a ≥ 4-fold increase in aztreonam minimum inhibitory concentration over 1 year and is above the parenteral breakpoint (> 8 μg/mL) [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    This proportion will be compared annually over 5 years.

Secondary Outcome Measures:
  • Annual mean change and mean change from baseline in FEV1 (liters) and FEV1 % predicted [ Time Frame: Baseline to Year 5 ] [ Designated as safety issue: No ]
  • Annual number of hospitalizations and the total number of hospitalizations at the end of each year [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • Annual number of days hospitalized and the total number of hospitalization days at the end of each year [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • Annual mean change and mean change from baseline in body mass index (BMI) [ Time Frame: Baseline to Year 5 ] [ Designated as safety issue: No ]
  • Annual number of Cayston treatment courses per participant and the total number of Cayston treatment courses at the end of each year in participants that used Cayston [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA
Pseudomonas aeruginosa isolates from sputum or throat swab specimens

Enrollment: 510
Study Start Date: August 2011
Estimated Study Completion Date: November 2016
Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
A representative cross-section of individuals with mild (FEV1 75% to ≤ 90% predicted), moderate (FEV1 40% to 74% predicted), or severe (FEV1 <40% predicted) lung disease and a history of ≥ 2 lower respiratory tract cultures positive for PA (at any time) will be enrolled. This will include approximately 100 individuals with pre-study exposure to Cayston (defined as having received at least one prior 28-day course of Cayston at any time before enrolling into the study). Enrollment will be monitored and potentially modified to ensure that adequate numbers of participants in each disease severity category are included. At the Investigator's discretion, participants enrolled in this study can be allowed to participate in clinical trials with other investigational therapies as appropriate.

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for participation in this study.

  • Current participant or willingness to participate in the CFF patient registry database
  • ≥ 6 years of age
  • Subject has CF as diagnosed by one of the following

    • Documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test, or
    • Two well-characterized genetic mutations in the CFTR gene, or
    • Abnormal nasal potential difference (NPD) AND accompanying clinical characteristics consistent with CF. For subjects who lack documentation of either a positive sweat chloride test or an abnormal NPD, and who have only one well-characterized genetic mutation of the CFTR gene, the diagnosis of CF is determined by the Investigator.
  • FEV1 ≥ 25% predicted and ≤ 90% predicted.
  • ≥ 2 lower respiratory tract cultures positive for PA with results documented in the subject's medical history.
  • Subject must be able to provide written informed consent/assent prior to any study related procedure; parent/guardian must be able to give written informed consent as necessary prior to any study related procedure.

Exclusion Criteria:

Subjects who meet the following exclusion criterion are not to be enrolled in this study.

• Any serious active medical or psychiatric illness that, in the opinion of the Investigator, would interfere with subject assessment.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01375036

  Show 31 Study Locations
Sponsors and Collaborators
Gilead Sciences
Cystic Fibrosis Foundation Therapeutics
Study Director: Mark Bresnik, MD Gilead Sciences
  More Information

Responsible Party: Gilead Sciences Identifier: NCT01375036     History of Changes
Other Study ID Numbers: GX-US-205-0128 
Study First Received: June 15, 2011
Last Updated: September 25, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Gilead Sciences:
Cystic fibrosis
Pseudomonas aeruginosa

Additional relevant MeSH terms:
Cystic Fibrosis
Disease Susceptibility
Pseudomonas Infections
Bacterial Infections
Digestive System Diseases
Disease Attributes
Genetic Diseases, Inborn
Gram-Negative Bacterial Infections
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Pharmacologic Actions
Therapeutic Uses processed this record on May 01, 2016